CELLECTIS news, videos and press releases - Page 3
For more news please use our advanced search feature.
CELLECTIS - More news...
CELLECTIS - More news...
- Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023
- Monthly information on share capital and company voting rights
- Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023
- Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors
- Monthly information on share capital and company voting rights
- Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023
- Monthly information on share capital and company voting rights
- Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023
- Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event
- Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
- Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023
- Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors
- Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023
- Monthly information on share capital and company voting rights
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023
- Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
- Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab
- Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting
- Monthly information on share capital and company voting rights
- Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22
- Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million
- Monthly information on share capital and company voting rights
- Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
- Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
- Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
- Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
- Monthly information on share capital and company voting rights
- Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares
- Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information
